Booster battle: which COVID-19 vaccine boosts immunity best?

NCT ID NCT05057169

Completed ⭐️ VACCINE ⭐️ Sponsor: The University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a third dose of either the CoronaVac or Comirnaty vaccine boosts immunity better in adults who had two prior doses at least six months earlier. Researchers measured antibody levels in 451 participants from Hong Kong 28 days after the booster. The goal was to see which booster triggers a stronger immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: COVID-19 booster vaccines (CoronaVac or Comirnaty)
What this could lead to: If successful, this could help determine which booster vaccine provides stronger immune protection after initial vaccination.
What could go wrong: This is a completed Phase 4 trial with 451 participants, so results are limited to antibody levels and may not reflect real-world protection against new variants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 VACCINATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 VACCINATION

Contacts and locations

Locations

The University of Hong Kong

Hong Kong, 00000, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.